sb24m
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 24, 2021 (NCT04895566)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Leukocyte surface antigen CD47ANTAGONIST
CD47
- TNF-alphaANTAGONIST
TNFA
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04895566 | Early Phase 1 (Phase 1) | May 24, 2021 | SWISS BIOPHARMA |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SWISS BIOPHARMA | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1